mor-14 has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Hashimoto, Y; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N; Wu, DJ | 1 |
| Arai, M; Chen, XH; Fujiwara, H; Fujiwara, T; Hashimoto, K; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N | 1 |
2 other study(ies) available for mor-14 and Disease Models, Animal
| Article | Year |
|---|---|
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Topics: 1-Deoxynojirimycin; Animals; Combined Modality Therapy; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart Ventricles; Ischemia; Ischemic Preconditioning, Myocardial; Lactic Acid; Myocardial Infarction; Rabbits | 2001 |
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blood Flow Velocity; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart; Lactic Acid; Male; Myocardial Ischemia; Myocardial Reperfusion; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Dysfunction, Left | 2000 |